Centene Corporation (CNC) $35.11
Centene Corporation (CNC) finds itself at a pivotal juncture, trading near its Bollinger Band midline at $35.11. While a strong technical confluence score hints at underlying strength, the stock remains in a precarious position, demanding patience from investors.
52-wk High $66.03
π Investment Snapshot
- π° CNC trades at $35.11, down 46.8% from its 52-week high, with negative TTM EPS.
- π Q4 2025 revenue hit $49.73B, but EPS remained deeply negative at $-2.24.
- π Strong technical confluence (80/100) and recent insider buying suggest potential for a bounce, despite a downtrend.
- π― Analysts rate CNC a ‘Hold’ with a mean target of $43.18, implying 22.96% upside.
Centene currently trades at $35.11, exhibiting a strong technical confluence score of 80/100, yet its RSI of 52.9 indicates it is not yet oversold. The stock sits below both its 50-day and 200-day SMAs, confirming a persistent downtrend.
| π Entry Zone | $32.88 or below | π Stop-Loss | $28.50 |
| π Adjust If | CNC reclaims the $37.00 level with sustained volume, signaling a shift in momentum. | ||
The Investment Case β Why Now?
Centene has seen significant price depreciation, dropping nearly 47% from its 52-week high, making it a potential value play for contrarian investors. The recent flurry of insider buying by directors, coupled with a robust technical confluence score of 80/100, suggests that smart money might be anticipating a turnaround. This confluence of factors, despite negative EPS, presents a compelling ‘wait-and-see’ scenario for a high-conviction dip.
The primary risk remains Centene’s deeply negative EPS, which has persisted for three consecutive quarters, culminating in a $-13.53 TTM EPS. This fundamental weakness could continue to weigh on investor sentiment, potentially driving the stock further down towards its 52-week low of $25.08, especially if future earnings reports fail to show a clear path to profitability.
π€ Given the strong technical signals but persistent negative EPS, are you willing to bet on a technical bounce before a fundamental turnaround?
π’ Company Overview
| Detail | Value |
|---|---|
| Company | Centene Corporation |
| Ticker / Exchange | CNC / NYSE |
| Sector / Industry | Healthcare / Healthcare Plans |
| CEO | Sarah M. London |
| Founded / HQ | 1984 / St. Louis, MO |
π Price Action & Technicals
Inside VA
Buy-side Sweep at $33.85 on 2026-03-31
Centene’s price action reveals a stock caught in a persistent downtrend, trading below both its 50-day SMA ($39.53) and 200-day SMA ($36.93). This technical setup typically signals continued bearish pressure, yet the current price sits precisely at the Bollinger Band midline, often a pivot point for either continuation or reversal.
Despite the downtrend, the MACD shows a nascent bullish cross, with the MACD line rising above its signal line, albeit still in negative territory. The ADX at 49.5 confirms a very strong trend, but the +DI (26.1) now exceeds the -DI (22.2), suggesting buying pressure is beginning to assert dominance within this established trend.
The Anchored VWAP from August 2025 at $35.45 currently sits just above the price, acting as immediate overhead resistance. Meanwhile, the Volume Profile’s Point of Control (POC) at $29.15 highlights a significant area of past trading activity and potential strong support, with the current price well within the Value Area.
Volume is running well below average at 62% of the 20-day average, indicating a lack of conviction behind recent price movements. However, the presence of two recent buy-side liquidity sweeps at $33.85 and $31.77 points to institutional interest stepping in at lower levels, potentially absorbing supply. The strong Technical Confluence Score of 80/100, driven by Volume Profile, Sweeps, ADX, and FVG, underscores a robust technical setup for a potential bounce, despite the prevailing bearish moving average alignment.
π€ With CNC's price below key moving averages but exhibiting strong technical confluence and recent buy-side sweeps, what specific price level would confirm a sustainable reversal for you?
β Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| CNC | Centene Corporation | N/A |
| UNH | UnitedHealth Group | 20.5x |
| ELV | Elevance Health | 15.0x |
| CI | Cigna Group | 11.0x |
| S&P 500 | Index Average | 21.0x |
π° Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| 2025-12-31 | $49.73B | $-2.24 | N/A |
| 2025-09-30 | $49.69B | $-13.50 | N/A |
| 2025-06-30 | $48.74B | $-0.51 | N/A |
| 2025-03-31 | $46.62B | $2.63 | N/A |
Centene generated $0.2 billion in Free Cash Flow in its latest quarter, a positive sign despite the negative EPS, indicating operational efficiency. The company did not report any share buybacks during this period, suggesting a focus on internal investments or debt management.
π Growth Drivers β What Moves the Stock
- Managed Care Demand π‘ Priced In β The broader healthcare plans sector continues to benefit from increasing demand for managed care services, driven by an aging population and expanding government programs. Centene, as a major player, is well-positioned to capture market share.
- Cost Management Initiatives π’ Upside Surprise β Management’s ongoing efforts to streamline operations and improve medical loss ratios could lead to a significant rebound in profitability. Any positive surprise in future earnings regarding these initiatives would be a major catalyst.
- Medicaid Expansion π‘ Priced In β Continued Medicaid expansion in various states provides a stable growth avenue for Centene, given its strong presence in government-sponsored healthcare programs.
π¦ Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Vanguard Group Inc | 56,978 |
| Blackrock Inc. | 44,396 |
| AQR Capital Management, LLC | 31,798 |
| State Street Corporation | 21,423 |
| Geode Capital Management, LLC | 13,271 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| COUGHLIN CHRISTOPHER J | Director | Mar 31, 2026 | Purchase | 1,140 |
| EPPINGER FREDERICK H | Director | Mar 31, 2026 | Purchase | 1,690 |
| SAMUELS THEODORE R II | Director | Mar 31, 2026 | Purchase | 943 |
| TANJI KENNETH Y. | Director | Mar 31, 2026 | Purchase | 1,179 |
| CASSO KATIE | Officer | Jan 26, 2026 | Purchase | 26,036 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 0.0% | 2.0 |
β Key Risk Factors
Significant EPS pressure
Policy-driven margin compression
Increased cost of capital
Market share erosion
π€ Considering the ongoing profitability challenges, what specific operational improvements or market shifts would you need to see to mitigate the risk of further downside?
π― Guidance & Wall Street View
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $70.0 | $43.18 | $32.0 | 17 | Hold |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| JP Morgan | Neutral | N/A | Mar 2026 | Maintains |
| Mizuho | Neutral | N/A | Mar 2026 | Maintains |
| Morgan Stanley | Equal-Weight | N/A | Mar 2026 | Maintains |
| Wells Fargo | Equal-Weight | N/A | Feb 2026 | Maintains |
| Cantor Fitzgerald | Neutral | N/A | Feb 2026 | Reiterates |
| Barclays | Overweight | N/A | Jan 2026 | Upgraded |
The analyst consensus rates Centene a ‘Hold,’ with a mean price target of $43.18, suggesting a 22.96% upside from current levels. While the sentiment is neutral, the target implies significant appreciation if the company can execute on its turnaround.
π Bull vs Bear β Probability-Weighted Scenarios
π Bull Case
- Successful execution of cost management initiatives drives a return to profitability sooner than expected, exceeding analyst expectations.
- Continued strong enrollment in government-sponsored programs, coupled with favorable policy developments, boosts revenue growth and margin expansion.
π Base Case
Centene navigates its operational challenges, gradually improving profitability while maintaining stable revenue growth. The stock consolidates around current levels before a slow, steady recovery towards the analyst consensus target.
π» Bear Case
- Profitability issues persist or worsen, leading to further analyst downgrades and a loss of investor confidence.
- Increased regulatory pressure or unexpected policy changes negatively impact Centene’s core business, driving the stock towards its 52-week lows.
π― Investor Action Plan β By Profile
Look for a reclaim of $37.00 with increased volume, targeting a move towards $40.00. A stop-loss below $34.00 is prudent to manage risk on any failed breakout.
Consider scaling into a position if CNC dips towards the $32.88-$33.79 bullish FVG zone, which aligns with recent buy-side sweeps. A long-term stop below $28.50 protects against a deeper decline.
While the long-term thesis for managed care remains intact, Centene’s current profitability challenges warrant caution. Monitor for a clear trend of improving EPS and FCF before committing significant capital, potentially initiating a position on a confirmed break above the 200-day SMA.
β Investor FAQ β People Also Ask
Q: Why is Centene’s EPS so negative, and what does it mean for investors?
Centene has reported deeply negative EPS for the past three quarters, with the latest at $-2.24. This indicates significant losses, likely stemming from higher medical costs or one-time charges, and signals a critical challenge for the company’s financial health.
Q: What do the recent insider purchases tell us about Centene’s outlook?
The recent insider buying by multiple directors on March 31, 2026, totaling over 4,900 shares, suggests internal confidence in Centene’s future prospects. While not a guarantee, such activity often precedes positive developments.
Q: How does the strong Technical Confluence Score of 80/100 reconcile with a ‘WAIT’ verdict?
The high Technical Confluence Score indicates a strong underlying technical setup for a potential bounce, driven by factors like Volume Profile and liquidity sweeps. However, the RSI (52.9) is not yet oversold, and the stock remains in a downtrend below key moving averages, justifying a ‘WAIT’ for a more optimal, lower-risk entry point.
π Want to check the current price action yourself?
π Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results.
All active positions and their real-time performance are tracked on our Investment Log.
#CNC #Centene #HealthcareStocks #StockAnalysis #NYSE #InvestmentStrategy